Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) expected in Q2 2026 Riad Sherif, M ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback